TORONTO: Nichi-Iko Pharmaceutical Co agreed to buy Sagent Pharmaceuticals Inc for US$736mil in cash, allowing the Japanese company to build its presence in the US market as it looks to become one of the world's top manufacturers of generic medicines.
Nichi-Ikowill pay US$21.75 per share, a premium of about 40% to Sagent's July 8 closing price, the companies said in a statement yesterday.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
